Abstract
In a case-control study of second primary cancers in Moscow, there were 165 cases and 294 controls, matched for site of first primary, duration of follow-up since first primary and relapse history. Of the cases, 18 were of acute, non-lymphocytic leukaemia (ANLL), with 39 matched controls. Risk of ANLL was assessed with respect to chemotherapy for the first primary tumour. The chemotherapeutic agents investigated were nitrogen mustard, cyclophosphamide, procarbazine, doxorubicin, bleomycin, vinblastine, vincristine, prednisone and combinations. Increased risks were associated with use of nitrogen mustard (odds ratio = 9.94, not significant), doxorubicin (odds ratio = 11.25, 0.1 > P > 0.05) and vincristine (odds ratio = 26.57, P < 0.05). Despite the small number of cases and potential confounding by other agents, these findings, together with those of previous studies, suggest that some non-alkylating agents may predispose to second malignancies.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- De Gramont A., Remes P., Krulik M., Smadja N., Drolet Y., Donadio D., Louvet C., Brissaud P., Sirinelli A., Dray C. Acute leukemia after treatment for ovarian cancer. Report of four cases and review of the literature. Oncology. 1986;43(3):165–172. doi: 10.1159/000226357. [DOI] [PubMed] [Google Scholar]
- Haas J. F., Kittelmann B., Mehnert W. H., Staneczek W., Möhner M., Kaldor J. M., Day N. E. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer. 1987 Feb;55(2):213–218. doi: 10.1038/bjc.1987.40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Henry-Amar M. Second cancers after radiotherapy and chemotherapy for early stages of Hodgkin's disease. J Natl Cancer Inst. 1983 Nov;71(5):911–916. [PubMed] [Google Scholar]
- Kaldor J. M., Day N. E., Clarke E. A., Van Leeuwen F. E., Henry-Amar M., Fiorentino M. V., Bell J., Pedersen D., Band P., Assouline D. Leukemia following Hodgkin's disease. N Engl J Med. 1990 Jan 4;322(1):7–13. doi: 10.1056/NEJM199001043220102. [DOI] [PubMed] [Google Scholar]
- Kaldor J. M., Day N. E., Pettersson F., Clarke E. A., Pedersen D., Mehnert W., Bell J., Høst H., Prior P., Karjalainen S. Leukemia following chemotherapy for ovarian cancer. N Engl J Med. 1990 Jan 4;322(1):1–6. doi: 10.1056/NEJM199001043220101. [DOI] [PubMed] [Google Scholar]
- Reimer R. R., Hoover R., Fraumeni J. F., Jr, Young R. C. Acute leukemia after alkylating-agent therapy of ovarian cancer. N Engl J Med. 1977 Jul 28;297(4):177–181. doi: 10.1056/NEJM197707282970402. [DOI] [PubMed] [Google Scholar]
- Tucker M. A., Coleman C. N., Cox R. S., Varghese A., Rosenberg S. A. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 1988 Jan 14;318(2):76–81. doi: 10.1056/NEJM198801143180203. [DOI] [PubMed] [Google Scholar]